GCM2: Key Regulator of Cell Cycle and Insulin Sensitivity (G9247)

Target Name: GCM2

NCBI ID: G9247

GCM2

GCM2: Key Regulator of Cell Cycle and Insulin Sensitivity

GCM2 (Gastrin-Cotranscriptional M2) is a protein that is expressed in various tissues throughout the body, including the liver, pancreas, and gastrointestinal tract. It is a key regulator of the cell cycle, and is involved in the development and maintenance of normal cell growth and differentiation. GCM2 has also been shown to play a role in the regulation of insulin sensitivity, and is a potential drug target for various diseases.

GCM2 is a member of the GCM2 family, which includes several related proteins that are involved in the regulation of the cell cycle. These proteins are characterized by the presence of a specific domain, known as the C-terminal transmembrane domain, which is responsible for the protein's ability to interact with other proteins and for its role in intracellular signaling.

GCM2 is a 21-kDa protein that is expressed in a variety of tissues, including the liver, pancreas, and gastrointestinal tract. It is primarily localized to the endoplasmic reticulum, where it is involved in the regulation of the cell cycle. GCM2 is thought to play a key role in the regulation of the G1 phase of the cell cycle, as well as the S phase.

In addition to its role in the cell cycle, GCM2 is also involved in the regulation of insulin sensitivity. Insulin sensitivity is the ability of cells to respond to insulin, and is an important factor in the development and progression of type 2 diabetes. GCM2 has been shown to play a role in the regulation of insulin sensitivity by affecting the levels of intracellular glucose.

GCM2 is also a potential drug target for various diseases, including cancer. Cancer is a disease that can be caused by a variety of factors, including genetic mutations, exposure to environmental toxins, and inflammation. GCM2 has been shown to be involved in the regulation of cancer cell growth and survival, and is therefore a potential target for cancer therapies.

GCM2 is also a potential biomarker for certain diseases. The diagnosis and treatment of many diseases is based on the measurement of specific biomarkers, which are indicators of the presence of a particular disease. GCM2 has been shown to be involved in the regulation of inflammation, and is therefore a potential biomarker for a variety of diseases, including cancer, autoimmune disorders, and gastrointestinal inflammatory diseases.

GCM2 is also a potential target for small molecule inhibitors. Small molecule inhibitors are a type of drug that can be used to reduce the activity of a particular protein or enzyme. GCM2 is a protein that is involved in the regulation of the cell cycle, and is therefore a potential target for small molecule inhibitors. By inhibiting the activity of GCM2, researchers may be able to prevent the regulation of the cell cycle and the development of cancer.

In conclusion, GCM2 is a protein that is involved in the regulation of the cell cycle and the regulation of insulin sensitivity. It is a potential drug target for various diseases, including cancer, and is also a potential biomarker for these diseases. Additionally, GCM2 is a target for small molecule inhibitors, which may be used to prevent the regulation of the cell cycle and the development of cancer. Further research is needed to fully understand the role of GCM2 in these processes and to develop effective treatments for these diseases.

Protein Name: Glial Cells Missing Transcription Factor 2

Functions: Transcription factor that binds specific sequences on gene promoters and activate their transcription. Through the regulation of gene transcription, may play a role in parathyroid gland development

The "GCM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GCM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets